The Burden of Prior Authorizations for Pediatric Pulmonary Hypertension Medications: A Quantitative Assessment

13 December 2025

Delphine Yung, Anne Davis, Kelly Merrill

https://doi.org/10.1002/pul2.70221 

 

Abstract

This study quantified prior authorization (PA)—insurance-required approval—burden for pediatric pulmonary hypertension (PH) at an accredited center. Among 53 patients, 72% of 283 prescriptions between 2021 and 2023 required PA, with non-FDA-approved medications showing highest volume. Despite 97% approval and all patients ultimately obtaining medication, delays (mean 4.2 days), repeat requests (39%), and reliance on patient assistance programs created significant administrative burden. Results highlight the need for policy reform to ensure timely, equitable access to essential therapies.

Read the full research letter

Share:

Other materials on this topic

1 December 2025

Beyond Resistance: Pulmonary Vascular Compromise as a Mechanistic Window Into Pediatric Pulmonary Hypertension

In the recent paper, Pulmonary Vascular Compromise is Associated with Survival in Pediatric Pulmonary Hypertension: a New Computational Model by Niccum et al. [1] presents an innovative computational model reframing pulmonary vascular disease through the concept of pulmonary vascular compromise (PVC), a quantifiable estimate of the proportion of pulmonary vascular surface area lost relative to an idealized normal pulmonary vascular capacity.

Pulmonary Circulation
14 November 2025

Challenges of Developing Novel Therapies for Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension

This webinar brings together leading experts to explore the urgent need for new therapies in bronchopulmonary dysplasia-associated pulmonary hypertension. You’ll gain a clear overview of current care, key research gaps, and the real-world challenges of designing meaningful trials for preterm infants — all aimed at advancing treatment for this under-recognised condition.

Members Only

More from Pulmonary Circulation

Show more details

A collection of up-to-date abstracts from our premier, international, peer-reviewed, medical research journal dedicated exclusively to pulmonary circulation and pulmonary vascular disease. 

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension
Assessing the Impact of Time to Diagnosis and Treatment for Patients With Pulmonary Arterial Hypertension
Real-World Performance of Sotatercept in PAH Patients With Cardiopulmonary Comorbidities: A Retrospective Single Center Experience
What I Learned From the Study of Sex Differences in Pulmonary Hypertension: How Following the Data and the Kindness of Strangers Helped Me Overcome Self-Doubt and Imposter Syndrome
From Patient-Specific Hemodynamic Modeling to Clinical Decision-Making in Chronic Thromboembolic Pulmonary Hypertension: Opportunities and Caveats
Rethinking Operability in Large VSD: The Diastolic Pulmonary Shunt Index (DiPSI) and a Probabilistic Perspective
A Lifelong Journey in the Field of the Pulmonary Circulation: Perspectives Through the Lens of the Cardiovascular Pulmonary Research Laboratory
Transitioning From Parenteral Prostanoids to Oral Selexipag in Pulmonary Arterial Hypertension: A Multicenter Retrospective Cohort Study
Improvement in Right Ventricular Function and Pulmonary Pressures in Patients With Severe Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction Treated With Sacubitril-Valsartan
Identification of Diagnostic Biomarkers Causally Associated With Gut Microbiota and Pulmonary Arterial Hypertension
Beyond Resistance: Pulmonary Vascular Compromise as a Mechanistic Window Into Pediatric Pulmonary Hypertension
Exploring the Impact of Platelet-Derived Growth Factor D in Pulmonary Hypertension Development
A Systematic Literature Review Exploring the Efficacy and Safety of Tadalafil and Sildenafil in Pulmonary Arterial Hypertension
Pulmonary Arterial Wedge Oxygen Saturation: Does It Confirm Wedge Position in Patients With Pulmonary Hypertension?
Progressive Pericardial Effusions (PEF) in Patients With Pulmonary Arterial Hypertension (PAH) Taking Sotatercept—Association With Pre-Existing Pericardial Effusion